ArticleESMO gastrointestinal oncology2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunotherapy for precision medicine in colorectal cancer.Expert review of precision medicine and drug development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective treatment for metastatic colorectal cancer (mCRC) remains an unmet need. CD47 overexpression on mCRC cells is associated with a poor prognosis. The ELEVATE CRC study evaluated magrolimab (CD47 inhibitor) plus bevacizumab-5-fluorouracil, irinotecan and leucovorin (FOLFIRI) in mCRC. Patients and methods: This open-label, phase II study enrolled eligible patients with previously treated advanced inoperable mCRC. The safety run-in (SRI) cohort's primary objective was to evaluate the safety, tolerability and recommended phase II dose of magrolimab plus bevacizumab-FOLFIRI. After SRI, patients were randomly assigned (2:1) to receive magrolimab plus bevacizumab-FOLFIRI (magrolimab) or bevacizumab-FOLFIRI (control). The randomised cohort's primary endpoint was progression-free survival (PFS). Results: No dose-limiting toxicities occurred in the SRI cohort (10 patients). In the randomised cohort (67 patients), median PFS was 6.2 versus 6.7 months in the magrolimab (44 patients) versus control (23 patients) arm (hazard ratio 0.956, 95% confidence interval 0.339-2.691). However, early study closure limits PFS interpretation. Grade ≥3 adverse event (AE) rates were 72.7% versus 52.4% in magrolimab versus control arms. Across cohorts, two AE-related deaths occurred in patients treated with magrolimab; neither was considered treatment-related. Conclusions: Adding magrolimab to bevacizumab-FOLFIRI increased grade ≥3 AE incidence and did not improve efficacy outcomes, highlighting a continuing unmet therapeutic need in mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.